Amycretin vs Retatrutide

    Amycretin (zenagamtide, NNC0487-0111) and Retatrutide (LY3437943) are two of the most discussed next-generation metabolic research compounds, and they share only one target. Amycretin is a single molecule acting on the GLP-1 and amylin receptors. Retatrutide is a single molecule acting on the GLP-1, GIP and glucagon receptors. This page compares them as research compounds.

    Available at Peptx

    Retatrutide

    UK single vials

    View

    Retalora

    Retatrutide 10mg + Eloralintide 2.5mg

    View

    Supplied for in-vitro research only.

    Development code
    NNC0487-0111 (zenagamtide)LY3437943
    Receptor targets
    GLP-1 and amylinGLP-1, GIP and glucagon
    Molecule
    One 68-amino-acid peptide: a GLP-1 analogue joined to an amylin agonistOne peptide acting on all three
    Forms in trials
    Once weekly and once-daily oralOnce weekly
    Headline result
    24.3% at 36 weeks, placebo 1.1% (125-person early study)TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9% (2,339 people)
    Status
    Phase 3 running since February 2026, none reportedPhase 3 reported and published
    Peptx availability
    Not stockedUK single vials and Factory Direct kits

    One shared target, two different additions

    Both compounds act on the GLP-1 receptor. Retatrutide adds the GIP receptor, which it shares with tirzepatide, and the glucagon receptor, which in animal studies raises energy expenditure. It has no amylin activity.

    Amycretin adds amylin instead. Amylin is a separate hormone system that acts on different brain circuits from the incretins. Until amycretin, amylin was added as a second molecule, as in cagrilintide with semaglutide. Amycretin joins the two activities in one peptide and has no GIP or glucagon activity.

    What the trials show

    Amycretin's largest reported figure comes from an early study published in The Lancet in 2025: 125 adults were randomised, and the highest-strength group lost an average of 24.3% of body weight at 36 weeks, against 1.1% on placebo. A phase 2 trial in type 2 diabetes, published in 2026, reported up to 14.5% at 36 weeks against 2.6% on placebo. Phase 3 trials began in February 2026 and none has reported.

    Retatrutide's TRIUMPH-1 phase 3 trial, published in the New England Journal of Medicine in September 2026, enrolled 2,339 adults and reported weight reductions of 17.6%, 23.7% and 25.0% at 80 weeks, against 3.9% on placebo.

    The amycretin figure comes from a small early study and the retatrutide figure from a large phase 3 trial, so the two cannot be ranked. No trial comparing them is registered.

    An oral form

    Amycretin is also being developed as a once-daily tablet, with a first-in-human study published in The Lancet in 2025 and a phase 3 trial registered. Retatrutide has been studied only as a once-weekly compound.

    Bottom line for research labs

    Amycretin and Retatrutide take different routes beyond GLP-1: amycretin adds amylin, retatrutide adds GIP and glucagon. Retatrutide has the published phase 3 record. Amycretin has striking early figures and an oral form, with phase 3 still to report. Labs studying amylin alongside a triple agonist currently work with retatrutide and a separate amylin agonist such as eloralintide or cagrilintide.

    Frequently asked questions

    Is amycretin the same as retatrutide?▼
    No. Amycretin acts on the GLP-1 and amylin receptors. Retatrutide acts on the GLP-1, GIP and glucagon receptors. They come from different developers and share only the GLP-1 target.
    Which reduced body weight more in trials?▼
    The headline figures are close: 24.3% at 36 weeks for amycretin in a 125-person early study, and up to 25.0% at 80 weeks for retatrutide in a 2,339-person phase 3 trial. The studies differ too much in size, length and design to rank the two, and they have never been compared directly.
    Is amycretin a quad agonist?▼
    No. Amycretin acts on two receptor systems, GLP-1 and amylin. The first single molecule reported to act on four (GLP-1, GIP, glucagon and amylin) is CT-G32, which has animal data only.
    Has either been approved?▼
    No. As of November 2026 neither amycretin nor retatrutide is approved anywhere.
    Can I buy both from Peptx?▼
    Retatrutide is available as UK single vials and Factory Direct kits, for in-vitro research only. Amycretin is not stocked.